Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.
作者信息
Anderson William F, Rosenberg Philip S, Katki Hormuzd A
机构信息
Affiliation of authors: Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (WFA, PSR, HAK).
出版信息
J Natl Cancer Inst. 2014 Apr 28;106(5):dju093. doi: 10.1093/jnci/dju093.
Abstract
摘要
相似文献
1
Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer.利用癌症登记数据追踪和评估分子肿瘤标志物：人表皮生长因子受体2与乳腺癌
J Natl Cancer Inst. 2014 Apr 28;106(5):dju093. doi: 10.1093/jnci/dju093.
2
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.美国联合激素受体和 HER2 状态定义的乳腺癌亚型发病率。
J Natl Cancer Inst. 2014 Apr 28;106(5):dju055. doi: 10.1093/jnci/dju055.
3
Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).雌激素受体、孕激素受体及Her2/neu均为阴性的乳腺癌（基底样乳腺癌）的免疫组化异质性
Mod Pathol. 2008 Aug;21(8):1060-1; author reply 1061-2. doi: 10.1038/modpathol.2008.67.
4
Descriptive analysis of molecular subtypes in Tunisian breast cancer.突尼斯乳腺癌分子亚型的描述性分析
Asia Pac J Clin Oncol. 2014 Jun;10(2):e69-74. doi: 10.1111/ajco.12034. Epub 2012 Nov 26.
5
The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.免疫组化显示“雌激素受体阴性、孕激素受体阴性、人表皮生长因子受体2阴性、细胞角蛋白5/6阴性及人表皮生长因子受体1阴性”的乳腺癌亚组并非类似正常亚型的替代指标。
Breast Cancer Res Treat. 2009 Dec;118(3):661-3. doi: 10.1007/s10549-009-0522-y.
6
Consuming a high-fat diet is associated with increased risk of certain types of BC.食用高脂肪饮食与某些类型乳腺癌的风险增加有关。
J Natl Cancer Inst. 2014 May;106(5). doi: 10.1093/jnci/dju114.
7
Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.根据免疫组织化学检测的四种生物标志物面板对乳腺癌分子亚型进行分类的特征和结局。
Breast. 2012 Feb;21(1):50-7. doi: 10.1016/j.breast.2011.07.008. Epub 2011 Aug 23.
8
Personalized medicine for breast cancer: it is a new day!乳腺癌个体化医学：新的一天！
Am J Surg. 2014 Mar;207(3):321-5. doi: 10.1016/j.amjsurg.2013.10.016. Epub 2013 Dec 27.
9
Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.原发性乳腺癌及其配对淋巴结转移灶中HER2、雌激素受体和孕激素受体的比较
Turk Patoloji Derg. 2016;32(3):178-85. doi: 10.5146/tjpath.2015.01354.
10
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.高Ki-67表达和低孕激素受体表达可独立导致雌激素受体阳性且人表皮生长因子受体2阴性的绝经后乳腺癌患者预后较差。
Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.
引用本文的文献
1
The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.乳腺癌生物标志物在诊断、预后及治疗监测中的评估：综合分析
J Cancer Res Clin Oncol. 2025 Aug 22;151(8):233. doi: 10.1007/s00432-025-06271-1.
2
Metabolic adaptations of brain metastasis.脑转移瘤的代谢适应性
Nat Rev Cancer. 2025 Jul 24. doi: 10.1038/s41568-025-00848-1.
3
Causal Effects of Breast Cancer Risk Factors across Hormone Receptor Breast Cancer Subtypes: A Two-Sample Mendelian Randomization Study.激素受体乳腺癌亚型中乳腺癌风险因素的因果效应：一项两样本孟德尔随机化研究
Cancer Epidemiol Biomarkers Prev. 2025 Jun 3;34(6):933-943. doi: 10.1158/1055-9965.EPI-24-1440.
4
Optimizing Premenopausal Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Management in India: Insights From Expert Consensus.优化印度绝经前激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌的管理：专家共识见解
Cureus. 2024 Dec 25;16(12):e76392. doi: 10.7759/cureus.76392. eCollection 2024 Dec.
5
Adiposity throughout Adulthood and Risk of Young-Onset Breast Cancer Tumor Subtypes in the Young Women's Health History Study.在年轻女性健康史研究中，成年期肥胖与早发型乳腺癌肿瘤亚型风险的关系。
Cancer Epidemiol Biomarkers Prev. 2024 Dec 2;33(12):1659-1670. doi: 10.1158/1055-9965.EPI-24-1067.
6
SCEL regulates switches between pro-survival and apoptosis of the TNF-α/TNFR1/NF-κB/c-FLIP axis to control lung colonization of triple negative breast cancer.SCEL 通过调节 TNF-α/TNFR1/NF-κB/c-FLIP 轴的生存和凋亡开关来控制三阴性乳腺癌的肺定植。
J Biomed Sci. 2023 Nov 30;30(1):93. doi: 10.1186/s12929-023-00986-4.
7
Recent Progress in Biosensors for Detection of Tumor Biomarkers.近年来用于肿瘤生物标志物检测的生物传感器的研究进展。
Molecules. 2022 Oct 28;27(21):7327. doi: 10.3390/molecules27217327.
8
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.乳腺癌：潜在耐药的分子机制与治疗方法
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.
9
Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.雌激素受体生物活性决定了雌激素受体阳性乳腺癌的临床内分泌治疗选择。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090351. doi: 10.1177/15330338221090351.
10
BTG2 as a tumor target for the treatment of luminal A breast cancer.BTG2作为治疗腔面A型乳腺癌的肿瘤靶点。
Exp Ther Med. 2022 May;23(5):339. doi: 10.3892/etm.2022.11269. Epub 2022 Mar 21.
本文引用的文献
1
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.美国联合激素受体和 HER2 状态定义的乳腺癌亚型发病率。
J Natl Cancer Inst. 2014 Apr 28;106(5):dju055. doi: 10.1093/jnci/dju055.
2
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.乳腺癌中的HER2受体：病理生理学、临床应用及治疗新进展
Chemother Res Pract. 2012;2012:743193. doi: 10.1155/2012/743193. Epub 2012 Dec 20.
3
Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer.利用基于人群的癌症登记处填补数据作为一种处理缺失信息的方法：在乳腺癌雌激素受体状态中的应用。
Am J Epidemiol. 2012 Aug 15;176(4):347-56. doi: 10.1093/aje/kwr512. Epub 2012 Jul 25.
4
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.乳腺癌亚型的年龄特异性发病率：理解黑-白交叉现象。
J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101. doi: 10.1093/jnci/djs264. Epub 2012 Jul 5.
5
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.2000 个乳腺肿瘤的基因组和转录组结构揭示了新的亚群。
Nature. 2012 Apr 18;486(7403):346-52. doi: 10.1038/nature10983.
6
Human papillomavirus and rising oropharyngeal cancer incidence in the United States.人乳头瘤病毒与美国口咽癌发病率的上升
J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
7
Incidence of breast cancer in the United States: current and future trends.美国乳腺癌的发病率：现状和未来趋势。
J Natl Cancer Inst. 2011 Sep 21;103(18):1397-402. doi: 10.1093/jnci/djr257. Epub 2011 Jul 13.
8
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.通过雌激素受体、孕激素受体和人表皮生长因子受体2来近似划分的乳腺癌亚型与保乳治疗后的局部和远处复发相关。
J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14.
9
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.人表皮生长因子受体2和雌激素受体表达，一项利用监测、流行病学和最终结果（SEER）计划的剩余组织储存库开展的示范项目。
Breast Cancer Res Treat. 2009 Jan;113(1):189-96. doi: 10.1007/s10549-008-9918-3. Epub 2008 Feb 7.
10
Carcinoma of the breast; results from statistical research.乳腺癌；统计研究结果
Br J Radiol. 1948 Dec;21(252):583-90. doi: 10.1259/0007-1285-21-252-583.
Zotero 插件